Edition:
United States

Paion AG (PA8G.DE)

PA8G.DE on Xetra

2.45EUR
17 Aug 2018
Change (% chg)

€0.12 (+5.15%)
Prev Close
€2.33
Open
€2.34
Day's High
€2.50
Day's Low
€2.34
Volume
57,211
Avg. Vol
45,312
52-wk High
€2.98
52-wk Low
€2.01

Latest Key Developments (Source: Significant Developments)

Paion Starts EU Phase III Trial With Remimazolam In General Anesthesia
Tuesday, 24 Jul 2018 03:58am EDT 

July 24 (Reuters) - PAION AG ::STARTS EU PHASE III TRIAL WITH REMIMAZOLAM IN GENERAL ANESTHESIA.PATIENT RECRUITMENT EXPECTED TO BE COMPLETED IN 2019.PAION - EXPECTS THAT POSITIVE PHASE III TRIAL WITH PREVIOUSLY COMPLETED CLINICAL STUDIES IN EUROPE AND JAPAN SHOULD BE SUFFICIENT FOR FILING FOR MARKET APPROVAL FOR INDICATION OF GENERAL ANESTHESIA IN EU.  Full Article

Paion AG Q1 Net Loss Amounted To EUR 3.1 Mln
Wednesday, 9 May 2018 01:29am EDT 

May 9 (Reuters) - Paion AG ::DGAP-NEWS: PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2018.NET LOSS FOR Q1 OF 2018 AMOUNTED TO KEUR 3,125 (PRIOR-YEAR PERIOD: KEUR 2,218).CONFIRMS ITS OUTLOOK FOR 2018 GIVEN IN MARCH 2018.CASH AND CASH EQUIVALENTS DECREASED BY KEUR 2,755 IN Q1 2018.  Full Article

Paion FY Net Loss At EUR 12.1 Million
Thursday, 22 Mar 2018 02:30am EDT 

March 22 (Reuters) - PAION AG ::SAYS FINANCIAL RESULTS IN LINE WITH PLAN.SAYS CASH AND CASH EQUIVALENTS OF EUR 24.8 MILLION AS OF 31 DECEMBER 2017.FY2017 REVENUES AMOUNTED TO EUR 5.8 MILLION INCREASED OF EUR 1.5 MILLION VERSUS TO PREVIOUS YEAR.GENERAL ADMINISTRATIVE AND SELLING EXPENSES AMOUNTED TO EUR 3.8 MILLION, A DECREASE OF EUR 1.3 MILLION VERSUS YEAR AGO.NET LOSS WAS EUR 12.1 MILLION, SIGNIFICANTLY LOWER THAN PRIOR YEAR FIGURE OF EUR 20.1 MILLION.CASH AND CASH EQUIVALENTS AS OF 31 DEC 2017 AMOUNTED TO EUR 24.8 MILLION, DECREASED EUR 5.3 MILLION VERSUS PRIOR YEAR.SAYS PAION EXPECTS REVENUES OF APPROX. EUR 3 MILLION IN 2018 - OUTLOOK.EXPECTS RESEARCH AND DEVELOPMENT EXPENSES TO BE BETWEEN APPROX. EUR 15 MILLION AND APPROX. EUR 17 MILLION.  Full Article

PAION Grants Exclusive License To Mundipharma For Development And Commercialization Of Remimazolam In Japan
Monday, 18 Dec 2017 12:45am EST 

Dec 18 (Reuters) - PAION AG ::SAID ON SUNDAY GRANTED EXCLUSIVE LICENSE TO MUNDIPHARMA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN JAPAN.EUR 1 MILLION UPFRONT PAYMENT TO PAION.ADDITIONAL REGULATORY AND COMMERCIAL MILESTONE PAYMENTS OF UP TO EUR 25 MILLION.ROYALTIES RANGING FROM LOW DOUBLE-DIGITS TO OVER 20%.  Full Article

PAION: FDA considers current human abuse liability program with remimazolam in U.S. as sufficient
Tuesday, 14 Nov 2017 04:15am EST 

Nov 14 (Reuters) - PAION AG :‍FDA CONSIDERS CURRENT HUMAN ABUSE LIABILITY PROGRAM WITH REMIMAZOLAM IN U.S. AS SUFFICIENT.‍NO SECOND INTRANASAL STUDY REQUIRED​.‍ASSUMES CLINICAL DEVELOPMENT PROGRAM FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN U.S. AS COMPLETED​.  Full Article

PAION ‍9-mth net loss at 8.5 mln euros
Wednesday, 8 Nov 2017 01:30am EST 

Nov 8 (Reuters) - PAION AG :DGAP-NEWS: PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2017.‍CASH POSITION OF EUR 29.6 MILLION AS OF 30 SEPTEMBER 2017​.‍REVENUES IN FIRST NINE MONTHS OF 2017 AMOUNTED TO KEUR 5,097 COMPARED TO KEUR 2,230 IN PRIOR-YEAR PERIOD​.‍RESEARCH AND DEVELOPMENT EXPENSES AMOUNTED TO KEUR 13,528 IN FIRST NINE MONTHS OF 2017​.‍9MTH NET LOSS AMOUNTED TO KEUR 8,508. IN PRIOR-YEAR PERIOD, A NET LOSS OF KEUR 16,061 WAS REPORTED​.‍CONFIRMS ITS OUTLOOK FOR FY ANNOUNCED ON 09 AUGUST 2017 WITH PUBLICATION OF HALF-YEAR RESULTS FOR 2017​.  Full Article

Paion: Japan patent office grants dosing patent for remimazolam
Friday, 13 Oct 2017 04:00am EDT 

Oct 13 (Reuters) - PAION AG ::DGAP-NEWS: PAION AG: JAPAN PATENT OFFICE GRANTS DOSING PATENT FOR REMIMAZOLAM IN JAPAN.‍PATENT PROTECTION UNTIL 2033 IN JAPANESE MARKET​.  Full Article

Paion H1 net loss narrows to 5.8 million euros
Wednesday, 9 Aug 2017 01:30am EDT 

Aug 9 (Reuters) - PAION AG ::‍IN FIRST HALF-YEAR 2017, REVENUES WERE EUR 4.1 MILLION​.‍NET LOSS FOR FIRST HALF-YEAR 2017 WAS EUR 5.8 MILLION COMPARED TO A NET LOSS OF EUR 13.2 MILLION IN PRIOR-YEAR PERIOD​.‍H1 RESEARCH AND DEVELOPMENT EXPENSES AMOUNTED TO EUR 9.9 MILLION, A DECREASE OF EUR 2.2 MILLION COMPARED TO FIRST HALF-YEAR 2016​.‍IN 2017, PAION EXPECTS REVENUES OF APPROXIMATELY EUR 5.8 MILLION​.FY ‍NET LOSS IS EXPECTED TO BE BETWEEN EUR 12 MILLION AND EUR 14 MILLION, A DECREASE COMPARED TO PRIOR YEAR (2016: EUR 20.1 MILLION)​.  Full Article

Paion AG says Remimazolam met its primary efficacy endpoint in U.S. Phase III clinical trial
Wednesday, 28 Jun 2017 02:15pm EDT 

June 28 (Reuters) - Paion Ag ::Positive headline data in U.S. Phase III trial with Remimazolam for procedural sedation undergoing bronchoscopy.Primary efficacy endpoint successfully achieved.Remimazolam met its primary efficacy endpoint in U.S. Phase III clinical trial in procedural sedation in patients undergoing bronchoscopy.  Full Article

Paion Q1 revenues at EUR 2.051 mln
Wednesday, 10 May 2017 01:44am EDT 

May 10 (Reuters) - PAION AG ::PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2017.REVENUES IN Q1 OF 2017 AMOUNTED TO EUR 2.051 MLN COMPARED TO EUR 3 MLN IN PRIOR-YEAR PERIOD.NET LOSS FOR Q1 2017 AMOUNTED TO EUR 2.218 MLN.CASH AND CASH EQUIVALENTS DECREASED BY EUR 1.379 MLN IN Q1 2017.PAION CONFIRMS ITS OUTLOOK FOR 2017 MADE ON 16 MARCH 2017 WITH PUBLICATION OF 2016 FINANCIAL RESULTS.PAION'S MAJOR GOALS FOR 2017 ARE CONTINUATION AND COMPLETION OF ONGOING CLINICAL DEVELOPMENT PROGRAM IN U.S. AND HANDOVER OF COMPLETED WORK TO COSMO.POSITIVE DATA ANNOUNCED IN U.S. SAFETY TRIAL WITH REMIMAZOLAM IN HIGH-RISK COLONOSCOPY PATIENTS.FINANCIAL RESULTS IN LINE WITH PLAN.  Full Article

BRIEF-Paion FY Net Loss At EUR 12.1 Million

* SAYS CASH AND CASH EQUIVALENTS OF EUR 24.8 MILLION AS OF 31 DECEMBER 2017